Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Italfarmaco S P A has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This case is handled by 1 distinct examiner, NOLAN, JASON MICHAEL, within 1 distinct art unit. NOLAN, JASON MICHAEL is the busiest examiner with 1 pending action, covering the company's entire active prosecution. This focused activity involves only one specific set of examiner requirements, which can simplify the management of the company's pharmaceutical intellectual property.
The concentration of the 1 pending office action within 1 distinct art unit allows the applicant to focus their technical arguments on the specific standards of that group. Because NOLAN, JASON MICHAEL is the only official involved, practitioners should prioritize understanding this 1 distinct examiner's past decisions and preferred claim structures. This streamlined prosecution path reduces the need for coordinating across different technical groups but also means the company's current biotech portfolio depends entirely on the resolution of this single matter. Success will require a strategy that directly addresses the 1 distinct art unit's standards.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOLAN, JASON MICHAEL | 1 | 66.6% | -27.2% |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18040708 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | NOLAN, JASON MICHAEL | 1623 | §112 | Non-Final OA | — | Pending | Feb 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialItalfarmaco S P A has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jason Michael Nolan has the most, with 1 of Italfarmaco S P A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
